U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
SpaceX IPO Forces Investors to Bet on Musk's Entangled AI Empire BloombergWhy We Think the SpaceX IPO Is Overvalued MorningstarBlackRock says 'mega forces' are changing investing. Here's what they say to do CNBCSpaceX Left California. Its IPO Payday Did Not. ForbesSpaceX's $1.78tn IPO asks investors to buy Musk's moonshots Financial Times
